Renpho

NIA announces funding for longevity clinical trials

Latest articles

The Sheekey Science Show: NAD+ rejuvenation strategies

NAD+ metabolism in aging & three strategies to rejuvenate. Welcome to The Sheekey Science Show! Longevity.Technology is delighted to partner with YouTube sensation Eleanor Sheekey (interviewed...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

BioAge kicks off Phase 2 longevity clinical trial

Company reveals primary indicator for BGE-117 clinical trial is unexplained anaemia of aging. Hot on the heels of its monster $90 million Series C funding...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Apollo Neuro

Editor's picks

The Sheekey Science Show: NAD+ rejuvenation strategies

NAD+ metabolism in aging & three strategies to rejuvenate. Welcome to The Sheekey Science Show! Longevity.Technology is delighted to partner with YouTube sensation Eleanor Sheekey (interviewed...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...
Renpho

New funding opportunity for longevity clinical trials from National Institute on Aging emphasises preventing aging and age-related disease.

The NIA, which is part of the National Institutes of Health, is inviting applications for longevity clinical trials to slow aging and prevent or treat age-related diseases.

Longevity.Technology: Previously, the FDA has approved biotech interventions that address individual diseases, rather than tackling aging itself. However, this funding opportunity is available to researchers who want to treat multiple chronic conditions by modulating fundamental aging-related mechanisms. In short, those who want to target aging itself. This paradigm shift in approach is fantastic news for longevity research, as the US Government puts its federal dollars where its mouth is.

Applications are invited for Phase 1, 2a and 2b clinical trials of new compounds or re-purposed existing drugs, biologics (except stem cells), or supplements to treat multiple chronic conditions by modulating fundamental aging-related mechanisms. The funding is also available to test compounds that could affect individual diseases and conditions that disproportionally affect older adults, although this funding opportunity application is not intended to provide support for definitive efficacy and safety trials.

This funding is open to a range of organisations based in the US, including universities, government research facilities, hospital research departments and private corporations. Applications must be submitted by 17th June of this year, with an earliest start date of April 2022 indicated.

 


 

The NIA intends to commit $4,500,000 in total costs in FY 2022 to fund 4-6 awards which is low considering the costs associated with later-stage clinical trials: but it’s a welcome start.

 


 

The NIA is clear about the change in focus that that this funding brings. “There is significant interest in the identification and testing in clinical trials of compounds that could treat individual or multiple age-related conditions by modulating fundamental aging-related mechanisms,” states the invitation. “A variety of compounds that modulate these processes have been extensively tested in model organisms, but just a few have crossed the translational divide between late-phase preclinical studies and early-phase clinical trials.”

The NIA defines longevity clinical trial stages as:

Phase 1 – focusing on assessing safety and tolerability, characterising the dose-limiting adverse reactions, determining the maximum tolerated dose and studying the pharmacokinetics (PK) and pharmacodynamics of new and repurposed molecular entities in healthy volunteers or in target patient populations.

Phase 2a – proof-of concept pilot studies to determine effects on clinical outcomes or predictors of clinical outcomes, the degree and specificity of molecular and cellular target engagement, off-target effects, and interactions with co-existing conditions and medications. Safety and efficacy testing may be done in a small number of patients. In addition, the optimal frequency of dose can be also explored in these types of trials.

Phase 2b – using rigorous scientific designs to inform decisions about the need for and feasibility of future definitive efficacy trials.

The NIA states that applicants are expected to propose trials of new and repurposed molecular entities in healthy volunteers or target patient populations that are designed to do the following:

  • Assess safety and tolerability, characterise the dose-limiting adverse reactions, or determine the maximum tolerated dose
  • Evaluate pharmacokinetics, pharmacodynamics, or interactions with co-existing conditions and medications
  • Evaluate select characteristics of safety and efficacy such as dose-response and routes of administration
  • Assess degree and specificity of molecular and cellular target engagement, and/or off-target effects
  • Generate evidence of early clinical efficacy and safety of interventions on intermediate clinical outcomes and/or predictors of clinical outcomes

$4.5m is a good start towards getting clinical trials in humans that target aging and prevent and treat multiple diseases underway. Clinical trials aren’t cheap and can often trigger more questions than they answer, so Longevity.Technology hopes that this funding opportunity is the first of many and that it represents a paradigm shift in the treatment of aging. Let’s tackle aging, and age-related diseases, early, aggressively and intelligently and ensure that longevity, both in terms of extended lifespan and improved healthspan, is a reasonable aspiration for everyone.

Image credit: Chokniti Khongchum / Pexels

Comment on this article

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.
Renpho

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...

It’s time to sit up and take notice of mitochondria

CohBar CEO on the development of a “true portfolio” of mitochondria based therapeutics. US biotech company CohBar is developing mitochondria-based therapeutics for the treatment of...
Apollo Neuro

Related articles

Mouse studies and safety to accelerate longevity drugs

Professor Mikhail Blagosklonny takes a look at therapeutic research done within the longevity field and concludes that there must be a re-focusing on lifespan...

The trillion dollar upside to longevity

New economic model estimates that targeting aging has larger economic gains than eradicating individual diseases: time for a policy pivot? Although life expectancy has increased...

International Day of Women and Girls in Science

As we celebrate International Day of Women and Girls in Science, here are just a few of the names to be found in our...

Open Life secures funding for longer, healthier lives

Open Life data project secures funding to help UK develop pandemic resilience and promote healthy life extension. The All Party-Parliamentary Group (APPG) for Longevity has...

British biotech success is longevity confidence boost

UK business confidence is at six-year high as biotech innovation and vaccine success dispel lockdown gloom. Data from IHS Markit demonstrates that British business confidence...
TruNigen pf